Loading
The trial that added toripalimab to chemotherapy for oesophageal cancer in China and showed a survival gain regardless of PD-L1 level.
514 patients. Median overall survival 17.0 versus 11.0 months (hazard ratio 0.58) and progression-free survival 5.7 versus 5.5 months (hazard ratio 0.58) at the interim analysis, with benefit independent of PD-L1 expression; published in Cancer Cell 2022. NMPA approval May 2022. One of five Chinese PD-1 trials (with ESCORT-1st, ORIENT-15, RATIONALE-306 and KEYNOTE-590) that made chemo-immunotherapy the first-line standard in a cancer where China has about half the world's cases.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Oesophageal cancer, Immune checkpoint inhibitors and the tag china.
Shares Toripalimab and the tag china.
Shares Oesophageal cancer and the tag china.
Shares Oesophageal cancer and the tag china.
Shares Immune checkpoint inhibitors and the tag china.
Shares Immune checkpoint inhibitors and the tag china.
Shares Immune checkpoint inhibitors and the tag china.
Shares Immune checkpoint inhibitors and the tag china.